Download PDF
CC BY 4.0 · Rev Bras Ginecol Obstet 2022; 44(09): 854-865
DOI: 10.1055/s-0042-1751287
Original Article
Sexology

Comparative Study of 150 vs. 200 Units of Botulinum Toxin as Treatment for Vaginismus

Estudo comparativo de 150 vs. 200 unidades de toxina botulínica como tratamento para vaginismo
Zeena R. Helmi 
1   Department of Gynecology and Obstetrics, College of Medicine, Mustansiriyah University, Baghdad, Iraq
› Author Affiliations
› Further Information
   Permissions and Reprints

Abstract

Objective To comparatively evaluate the outcome of treatment with 150 versus 200 units (U) of botulinum toxin in achieving pain-free intercourse and relieving muscle contraction in order to allow gynecological examination.

Methods In this comparative prospective observational study, 99 patients with vaginismus were treated with botulinum toxin injections from September 2016 to August 2021. Diagnosis and grading of vaginismus severity were assessed using a Female Sexual Function Index (FSFI) questionnaire. Under local or general anesthesia, botulinum toxin diluted with preservative-free saline (150 U and 200 U) was injected into, above, and below the right and left bulbospongiosus muscle and the lateral submucosal areas of the introitus and perineal body using an insulin syringe. Patients were recalled after 2 weeks, and the postoperative outcome was recorded using a similar preoperative questionnaire.

Results Overall, the mean age of patients was 30.2 years. The baseline and clinical characteristics were comparable between the 2 groups (p > 0.05). Significant improvements were seen in the pain and anxiety scores of finger penetration, dilator use, intercourse, and cotton swab in individual groups. The intergroup comparisons between 150 U and 200 U of Botox were not statistically significant (p > 0.05).

Conclusion Low-dose Botox (150 U) is equally effective as high dose Botox injections (200 U) in vaginismus patients. Therefore, Botox-150 U can be used to treat vaginismus as an alternative to high doses of the same substance.

Resumo

Objetivo Avaliar comparativamente o resultado do tratamento com 150 versus 200 unidades (U) de toxina botulínica na obtenção de relações sexuais sem dor e no alívio da contração muscular para permitir o exame ginecológico.

Métodos Neste estudo observacional prospectivo comparativo, 99 pacientes com vaginismo foram tratadas com injeções de toxina botulínica de setembro de 2016 a agosto de 2021. O diagnóstico e a classificação da gravidade do vaginismo foram avaliados usando um questionário Female Sexual Function Index (FSFI). Sob anestesia local ou geral, injetou-se toxina botulínica diluída em soro fisiológico sem conservantes (150 U e 200 U) nos músculos bulbo esponjoso direito e esquerdo e nas áreas submucosas laterais do intróito e corpo perineal, utilizando-se uma seringa de insulina. Os pacientes foram chamados após 2 semanas, e o resultado pós-operatório foi registrado usando um questionário pré-operatório semelhante.

Resultados No geral, a média de idade dos pacientes foi de 30,2 anos. As características basais e clínicas foram comparáveis entre os 2 grupos (p > 0,05). Melhorias significativas foram observadas nos escores de dor e ansiedade à penetração com dedo, uso de dilatador, relação sexual e cotonete em grupos individuais. As comparações intergrupos entre 150 U e 200 U Botox foram não estatisticamente significativas (p > 0,05).

Conclusão Botox de baixa dose (150 U) é tão eficaz quanto injeções de Botox de alta dose (200 U) em pacientes com vaginismo. Portanto, o Botox-150 U pode ser usado para tratar o vaginismo como alternativa às altas doses da mesma substância.

Keywords

vaginismus - botulinum toxin - sexual pain - anxiety - pain treatment

Palavras-chave

vaginismo - toxina botulínica - dor sexual - ansiedade - tratamento da dor


Publication History

Received: 12 February 2022

Accepted: 24 May 2022

Article published online:
11 July 2022

© 2022. Federação Brasileira de Ginecologia e Obstetrícia. This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting unrestricted use, distribution, and reproduction so long as the original work is properly cited. (https://creativecommons.org/licenses/by/4.0/)

Thieme Revinter Publicações Ltda.
Rua do Matoso 170, Rio de Janeiro, RJ, CEP 20270-135, Brazil

 

  • References

  • 1 Boyer SC, Goldfinger C, Thibault-Gagnon S, Pukall CF. Management of female sexual pain disorders. Adv Psychosom Med 2011; 31: 83-104
    CrossrefPubMedSearch in Google Scholar
  • 2 Ferreira JR, Souza RP. Botulinum toxin for vaginismus treatment. Pharmacology 2012; 89 (5-6): 256-259
    CrossrefPubMedSearch in Google Scholar
  • 3 Velayati A, Jahanian Sadatmahalleh S, Ziaei S, Kazemnejad A. The role of personal factors in quality of life among Iranian women with vaginismus: a path analysis. Health Qual Life Outcomes 2021; 19 (01) 166
    CrossrefPubMedSearch in Google Scholar
  • 4 Yaraghi M, Ghazizadeh S, Mohammadi F, Ashtiani EM, Bakhtiyari M, Mareshi SM. et al. Comparing the effectiveness of functional electrical stimulation via sexual cognitive/behavioral therapy of pelvic floor muscles versus local injection of botulinum toxin on the sexual functioning of patients with primary vaginismus: a randomized clinical trial. Int Urogynecol J Pelvic Floor Dysfunct 2019; 30 (11) 1821-1828
    CrossrefPubMedSearch in Google Scholar
  • 5 American Psychiatric Association. Diagnostic and statistical manual of mental disorders: DSM-5. 5th ed.. Washington (DC): American Psychiatric Association; 2013
    CrossrefSearch in Google Scholar
  • 6 Topdagi Yilmaz EP, Oral Ahiskalioglu E, Ahiskalioglu A, Tulgar S, Aydin ME, Kumtepe Y. A novel multimodal treatment method and pilot feasibility study for vaginismus: initial experience with the combination of sacral erector spinae plane block and progressive dilatation. Cureus 2020; 12 (10) e10846
    CrossrefPubMedSearch in Google Scholar
  • 7 World Health Organization. International Classification of Diseases (ICD) [Internet]. 2021 [cited 2021 May 27]. Available from: https://www.who.int/standards/classifications/classification-of-diseases
    PubMedSearch in Google Scholar
  • 8 Dick B, Natale C, Reddy A, Akula KP, Yousif A, Hellstrom WJG. Application of botulinum neurotoxin in female sexual and genitourinary dysfunction: a review of current practices. Sex Med Rev 2021; 9 (01) 57-63
    CrossrefPubMedSearch in Google Scholar
  • 9 Velayati A, Jahanian Sadatmahalleh S, Ziaei S, Kazemnejad A. Can Botox offer help women with vaginismus? A systematic review and meta-analysis. Int J Sex Health 2019; 31 (03) 233-243
    CrossrefPubMedSearch in Google Scholar
  • 10 Fageeh WM. Different treatment modalities for refractory vaginismus in western Saudi Arabia. J Sex Med 2011; 8 (06) 1735-1739
    CrossrefPubMedSearch in Google Scholar
  • 11 Michetti PM, Silvaggi M, Fabrizi A, Tartaglia N, Rossi R, Simonelli C. Unconsummated marriage: can it still be considered a consequence of vaginismus?. Int J Impot Res 2014; 26 (01) 28-30
    CrossrefPubMedSearch in Google Scholar
  • 12 Zheng Z, Yin J, Cheng B, Huang W. Materials selection for the injection into vaginal wall for treatment of vaginal atrophy. Aesthetic Plast Surg 2021; 45 (03) 1231-1241
    CrossrefPubMedSearch in Google Scholar
  • 13 Rosen R, Brown C, Heiman J, Leiblum S, Meston C, Shabsigh R. et al. The Female Sexual Function Index (FSFI): a multidimensional self-report instrument for the assessment of female sexual function. J Sex Marital Ther 2000; 26 (02) 191-208
    CrossrefPubMedSearch in Google Scholar
  • 14 Yule MA. Female Sexual Function Index. In: Michalos AC. editors. Encyclopedia of quality of life and well-being research. Dordrecht: Springer; 2014: 2244-6
    Search in Google Scholar
  • 15 Achour R, Koch M, Zgueb Y, Ouali U, Ben Hmid R. Vaginismus and pregnancy: epidemiological profile and management difficulties. Psychol Res Behav Manag 2019; 12: 137-143
    CrossrefPubMedSearch in Google Scholar
  • 16 Anğın AD, Gün İ, Sakin Ö, Çıkman MS, Eserdağ S, Anğın P. Effects of predisposing factors on the success and treatment period in vaginismus. JBRA Assist Reprod 2020; 24 (02) 180-188
    CrossrefPubMedSearch in Google Scholar
  • 17 Pacik PT, Babb CR, Polio A, Nelson CE, Goekeler CE, Holmes LN. Case series: redefining severe grade 5 vaginismus. Sex Med 2019; 7 (04) 489-497
    CrossrefPubMedSearch in Google Scholar
  • 18 Maasoumi R, Lamyian M, Montazeri A, Azin SA, Aguilar-Vafaie ME, Hajizadeh E. The sexual quality of life-female (SQOL-F) questionnaire: translation and psychometric properties of the Iranian version. Reprod Health 2013; 10: 25
    CrossrefPubMedSearch in Google Scholar
  • 19 Coşkuner Potur D, Güngör Satilmiş I, Doğan Merih Y, Gün Kakaşçi Ç, Demirci N, Ersoy M. Does infertility affect the sexual function and sexual quality of life of women? A case control study. Int J Sex Health 2020; 32 (01) 22-32
    CrossrefPubMedSearch in Google Scholar
  • 20 Fugl-Meyer KS, Bohm-Starke N, Damsted Petersen C, Fugl-Meyer A, Parish S, Giraldi A. Standard operating procedures for female genital sexual pain. J Sex Med 2013; 10 (01) 83-93
    CrossrefPubMedSearch in Google Scholar
  • 21 Foster L, Clapp L, Erickson M, Jabbari B. Botulinum toxin A and chronic low back pain: a randomized, double-blind study. Neurology 2001; 56 (10) 1290-1293
    CrossrefPubMedSearch in Google Scholar
  • 22 Chen CL, Meng E. Can botulinum toxin A play a role in treatment of chronic pelvic pain syndrome in female patients?—Clinical and animal evidence. Toxins (Basel) 2020; 12 (02) 110
    CrossrefPubMedSearch in Google Scholar
  • 23 Gari R, Alyafi M, Gadi RU, Gadi SU. Use of Botulinum Toxin (Botox®) in cases of refractory pelvic floor muscle dysfunction. Sex Med Rev 2022; 10 (01) 155-161
    CrossrefPubMedSearch in Google Scholar
  • 24 Ghazizadeh S, Nikzad M. Botulinum toxin in the treatment of refractory vaginismus. Obstet Gynecol 2004; 104 (5 Pt 1): 922-925
    CrossrefPubMedSearch in Google Scholar
  • 25 Karp BI, Tandon H, Vigil D, Stratton P. Methodological approaches to botulinum toxin for the treatment of chronic pelvic pain, vaginismus, and vulvar pain disorders. Int Urogynecol J Pelvic Floor Dysfunct 2019; 30 (07) 1071-1081
    CrossrefPubMedSearch in Google Scholar
  • 26 Ghazizadeh S, Abedi J, Pourmatroud AJ, Raiisi F, Lesanpezeshki M. Comparison of 500 units vs 250 units of botulinum toxin (abobotulinumtoxinA) for the treatment of severe vaginismus. J Bacteriol Mycol (Monroe Township) 2016; 3 (03) 1033-1036
    PubMedSearch in Google Scholar
  • 27 Park AJ, Paraiso MFR. Successful use of botulinum toxin type a in the treatment of refractory postoperative dyspareunia. Obstet Gynecol 2009; 114 (2 Pt 2): 484-487
    CrossrefPubMedSearch in Google Scholar
  • 28 Shafik A, El-Sibai O. Study of the pelvic floor muscles in vaginismus: a concept of pathogenesis. Eur J Obstet Gynecol Reprod Biol 2002; 105 (01) 67-70
    CrossrefPubMedSearch in Google Scholar
  • 29 Moga MA, Dimienescu OG, Bălan A, Scârneciu I, Barabaș B, Pleș L. Therapeutic approaches of botulinum toxin in gynecology. Toxins (Basel) 2018; 10 (04) 169
    CrossrefPubMedSearch in Google Scholar
  • 30 Pacik PT. Understanding and treating vaginismus: a multimodal approach. Int Urogynecol J Pelvic Floor Dysfunct 2014; 25 (12) 1613-1620
    CrossrefPubMedSearch in Google Scholar
  • 31 Bertolasi L, Frasson E, Cappelletti JY, Vicentini S, Bordignon M, Graziottin A. Botulinum neurotoxin type A injections for vaginismus secondary to vulvar vestibulitis syndrome. Obstet Gynecol 2009; 114 (05) 1008-1016
    CrossrefPubMedSearch in Google Scholar
  • 32 Molaeinezhad M, Khoei EM, Salehi M, Yousfy A, Roudsari RL. Validation of the partner version of the multidimensional vaginal penetration disorder questionnaire: A tool for clinical assessment of lifelong vaginismus in a sample of Iranian population. J Educ Health Promot 2014; 3: 114
    CrossrefPubMedSearch in Google Scholar
  • 33 Rahman S. Female sexual dysfunction among muslim women: increasing awareness to improve overall evaluation and treatment. Sex Med Rev 2018; 6 (04) 535-547
    CrossrefPubMedSearch in Google Scholar
  • 34 Anğın AD, Gün İ, Sakin Ö, Çıkman MS, Eserdağ S, Anğın P. Effects of predisposing factors on the success and treatment period in vaginismus. JBRA Assist Reprod 2020; 24 (02) 180-188
    CrossrefPubMedSearch in Google Scholar
  • 35 Butrick CW. Pelvic floor hypertonic disorders: identification and management. Obstet Gynecol Clin North Am 2009; 36 (03) 707-722
    CrossrefPubMedSearch in Google Scholar
  • 36 Brueseke TJ, Lane FL. Ischiorectal fossa abscess after pelvic floor injection of botulinum toxin. Am J Obstet Gynecol 2012; 206 (03) e7-e8
    CrossrefPubMedSearch in Google Scholar
  • 37 Weinberger JM, Houman J, Caron AT, Anger J. Female sexual dysfunction: a systematic review of outcomes across various treatment modalities. Sex Med Rev 2019; 7 (02) 223-250
    CrossrefPubMedSearch in Google Scholar
  • 38 Diomande I, Gabriel N, Kashiwagi M, Ghisu GP, Welter J, Fink D. et al. Subcutaneous botulinum toxin type A injections for provoked vestibulodynia: a randomized placebo-controlled trial and exploratory subanalysis. Arch Gynecol Obstet 2019; 299 (04) 993-1000
    CrossrefPubMedSearch in Google Scholar
  • 39 Weinberger JM, Houman J, Caron AT, Patel DN, Baskin AS, Ackerman AL. et al. Female sexual dysfunction and the placebo effect: a meta-analysis. Obstet Gynecol 2018; 132 (02) 453-458
    CrossrefPubMedSearch in Google Scholar
  • 40 Zargooshi J. Male sexual dysfunction in unconsummated marriage: long-term outcome in 417 patients. J Sex Med 2008; 5 (12) 2895-2903
    CrossrefPubMedSearch in Google Scholar
  • 41 Basson R, Wierman ME, van Lankveld J, Brotto L. Summary of the recommendations on sexual dysfunctions in women. J Sex Med 2010; 7 (1 Pt 2): 314-326
    CrossrefPubMedSearch in Google Scholar
  • 42 Maseroli E, Scavello I, Rastrelli G, Limoncin E, Cipriani S, Corona G. et al. Outcome of medical and psychosexual interventions for vaginismus: a systematic review and meta-analysis. J Sex Med 2018; 15 (12) 1752-1764
    CrossrefPubMedSearch in Google Scholar